Novo Nordisk researches, develops, manufactures, and distributes pharmaceutical products across two segments: Obesity and Diabetes Care, and Rare Disease. The company kicked off 2026 with its explosive obesity pill launch, but faces challenges in protecting market share in the blockbuster weight loss drug market. Around 246,000 patients are currently on Novo's Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.
Cyborg Score Rationale
While the company demonstrated strong 2025 sales growth driven by obesity treatments, mounting pricing pressure, transformation costs, and intensifying competition in the global GLP-1 market are tempering operating profits and creating headwinds. The Wegovy pill launch shows innovation capability, but competition from Eli Lilly and U.S. pricing pressure are expected to erode the multibillion-dollar obesity drug business, with 2026 forecasting sales and profit declines that shook investors and erased nearly $50 billion in market value.
Top Insights
2025 delivered 10% sales growth but 2026 faces significant headwinds from pricing pressure, transformation costs, and intensifying GLP-1 competition.
Wegovy pill launched January 2026 with 246,000 patients already enrolled, with 88% taking the starter dose, signaling pent-up demand for oral options.
2026 growth is countered by lower realized prices from MFN agreements in the US and loss of semaglutide exclusivity in certain international markets.
The company employs about 68,800 people in 80 countries and markets its products in around 170 countries.
Named Competitors
Zepbound — GLP-1 receptor agonist for obesity management
Mounjaro — Tirzepatide for diabetes and emerging obesity uses
Compounded Semaglutide — Unapproved generic alternatives at lower cost
Recent Developments
(February 2026) Novo Nordisk reports 2025 sales growth of 10% at CER and forecasts 2026 sales/profit declines of 5-13%
(January 2026) Wegovy oral semaglutide launches with exceptional early uptake and 246,000 patients already enrolled
(December 2025) FDA approves Wegovy pill; Novo initiates $2.1 billion share repurchase program
(2025) Akero Therapeutics acquisition announced to expand MASH portfolio; cagrilintide phase 3 initiated for weight management
Open the full interactive Novo Nordisk A/S report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.